Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis.
Investigation of monkey neurovirulence of dengue-3 viruses (DEN-3, 16562) was undertaken to provide an evaluation of the relative safety of virus strain attenuated for potential use of live virus vaccine. Ten flavivirus-negative, cynomolgus monkeys (Macacafascicularis) were used in the test. The animals were inoculated intrathalamically, intraspinally and intramuscularly with DEN-3 PGMK 33 attenuated live virus vaccine (6 monkeys): parent virus (2) and control cell culture fluid (2). Blood samples were collected on days 0, 1, 2, 4, 6, 8, 10, 12 and 21 for virus isolation and days 0 and 21 or 22 for serologic testing. One monkey with DEN-3 (16562) PGMK 33 candidate vaccine had detectable viremia on day 10. By day 21, all recipients of PGMK 33 and both monkeys with DEN-3 parent virus developed serum neutralizing antibodies to DEN-3 titers ranged from 56-320. The monkeys showed no evidence of illness and none died of dengue infection. Histopathological examination of tissue collected on day 21 or 22 revealed only minimal neurovirulence lesions as scored by the routine grading system. No differences were observed between the DEN-3 parent and vaccine viruses and it is concluded that neither virus is neurovirulent for cynomolgus monkeys.
Angsubhakorn
S
S
Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Yoksan
S
S
Pradermwong
A
A
Nitatpattana
N
N
Sahaphong
S
S
Bhamarapravati
N
N
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002490:Central Nervous System / Q000473:pathology; D003716:Dengue Virus / Q000276:immunology / Q000472:pathogenicity*; D008252:Macaca fascicularis; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*; D014766:Viremia; D014774:Virulence
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines